← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Carmot Therapeutics, Inc.
San Francisco, CA
$3,252,403
Total funding
5
Grants
Funding over time
peak $1.2M · FY2010–14$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,052,405 · 4
NSF$199,998 · 1
By mechanism
R44$1,911,764 · 1
R43$1,140,641 · 3
—$199,998 · 1
Investigators at Carmot Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$987,616
R44 · FY2013 · CA
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of$924,148
R44 · FY2014 · CA
Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o$322,632
R43 · FY2012 · DK
A novel approach to discover selective small molecule inhibitors of FABP4 and FAB$299,807
R43 · FY2011 · DK
Discovery of small molecule drug candidates that disrupt the NEMO/IKK signaling c$299,307
R43 · FY2010 · CA
Discovery of biased small molecule agonists of the GLP-1 receptor for treatment o$218,895
R43 · FY2013 · DK
SBIR Phase I: A new drug discovery method to transform peptides to small molecules: proof of principle with p53-hdm2$199,998
· FY2010 · TIP